Clinical Trials on Varicella (Chickenpox) in Czechia

Total 17 results

GlaxoSmithKline

Completed

Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients

Varicella

Czechia
GlaxoSmithKline

Completed

Study of Two Formulations of GSK Biologicals' Varicella Vaccine

Varicella

Czechia, Hungary
GlaxoSmithKline

Completed

Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox

Varicella | Chickenpox Vaccines

Russian Federation, Romania, Czechia, Slovakia, Italy, Sweden, Poland, Greece, Norway, Lithuania
GlaxoSmithKline

Completed

Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects

Herpes Zoster

Germany, Czechia, Sweden, Netherlands
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older

Herpes Zoster

Germany, Czechia, Sweden
GlaxoSmithKline

Completed

Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects

Herpes Zoster

Germany, Czechia, Sweden, Netherlands
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

Herpes Zoster

United States, Spain, Czechia
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant

Herpes Zoster

Spain, Taiwan, Italy, Canada, Belgium, Finland, Korea, Republic of, Panama, Czechia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

Herpes Zoster | Herpes Zoster Vaccine

Canada, Spain, Korea, Republic of, United Kingdom, France, Czechia
GlaxoSmithKline

Completed

A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022

Herpes Zoster

United States, Australia, Germany, Spain, Japan, Taiwan, Sweden, Korea, Republic of, Hong Kong, Mexico, Canada, France, Italy, Brazil, Estonia, United Kingdom, Czechia, Finland
GlaxoSmithKline

Active, not recruiting

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Herpes Zoster

United States, Australia, Finland, Germany, Japan, Taiwan, Sweden, Spain, Korea, Republic of, Brazil, Mexico, Italy, Canada, Czechia, Estonia, France, Hong Kong, United Kingdom
GlaxoSmithKline

Completed

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Herpes Zoster

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Sweden, Korea, Republic of, Brazil, Mexico, Canada, Italy, France, Czechia, Estonia, Hong Kong, United Kingdom
GlaxoSmithKline

Completed

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

Herpes Zoster

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom
GlaxoSmithKline

Completed

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

Herpes Zoster

France, Spain, Taiwan, Belgium, Singapore, United States, Hong Kong, Russian Federation, Finland, Korea, Republic of, Czechia, Australia, Canada, Sweden, Poland, United Kingdom, Panama, Italy, Turkey, Pakistan, New Zealand
GlaxoSmithKline

Completed

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

Herpes Zoster

United States, Australia, France, Spain, Finland, Estonia, Russian Federation, Taiwan, Belgium, Korea, Republic of, Czechia, Germany, Hong Kong, Israel, Turkey, United Kingdom, Greece, Romania, Netherlands, Italy, South Africa, Ca... and more
GlaxoSmithKline

Completed

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

Herpes Zoster

United States, Australia, Germany, Spain, Finland, Japan, Taiwan, Sweden, Korea, Republic of, Hong Kong, Mexico, Canada, Italy, France, Brazil, Estonia, United Kingdom, Czechia
GlaxoSmithKline

Completed

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

Herpes Zoster | Herpes Zoster Vaccine

United States, Australia, Spain, Finland, Germany, Japan, Taiwan, Canada, Sweden, Korea, Republic of, Czechia, Hong Kong, Mexico, Italy, Brazil, Estonia, France, United Kingdom

Clinical Trials on Varicella (Chickenpox) in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations